Nevin Abernethy - Anteo Diagnostics Insider

Anteo Diagnostics Limited -- Australia Stock  

AUD 0.02  0.00  0.00%

Chief Product Development and Research Officer

Dr. Nevin Abernethy Ph.D. is Chief Product Development and Research Officer of Anteo Diagnostics Limited. He was awarded his PhD in animal physiology by the University of Toronto Canada in 1989. After working as a Research Officer and lecturer at the University of Melbournes Department of Veterinary and PreClinical Sciences he moved to Auckland New Zealand where he was a Research Fellow in the Department of Molecular Medicine at the University of Auckland prior to joining Genesis Research and Development Corporationration at the time the biotech company in New Zealand. Nevin is named as an inventor on a number of patents in the area of therapeutics and immunological diseases has published numerous peer reviewed papers in related areas and has demonstrated in product development programs similar to those of interest to BioLayer.
  Executive Since 2007      
61 7 3219 0085  http://www.anteodx.com

Management Efficiency

The company has return on total asset (ROA) of (2.66) % which means that it has lost $2.66 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (68.77) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 677.27 K in total debt with debt to equity ratio (D/E) of 11.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Anteo Diagnostics Limited has Current Ratio of 1.15 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Anna LenahanCommonwealth Bank of Australia
2016
Kathryn MerweAustralia and New Zealand Banki
2017
Gregory LilleymanRio Tinto Limited
2014
David CurranWestpac Banking Corporation
2014
Vera KirikovaRio Tinto Limited
2017
Maile CarnegieAustralia and New Zealand Banki
2016
Harry KenyonSlaneyRio Tinto Limited
2012
Christine ParkerWestpac Banking Corporation
2011
Stephen McIntoshRio Tinto Limited
2016
Gary ThursbyWestpac Banking Corporation
2016
Melanie LaingCommonwealth Bank of Australia
2012
Geoff HealyBHP Billiton Limited
2016
John PriestleyAustralia and New Zealand Banki
2017
Philip RichardsRio Tinto Limited
2017
Simon TrottRio Tinto Limited
2017
Carla CollingwoodCommonwealth Bank of Australia
2005
Tim PaineRio Tinto Limited
2012
Kelly RosmarinCommonwealth Bank of Australia
2013
Clare McManusCommonwealth Bank of Australia
2017
Bob SantamariaAustralia and New Zealand Banki
2017
David StephenWestpac Banking Corporation
2018

Entity Summary

Anteo Diagnostics Limited, a medical technology company, develops and commercializes specialized surfaces for use in life sciences industries in Australia. Anteo Diagnostics Limited (ADO) is traded on Australian Securities Exchange in Australia. It is located in Eight Mile Plains, QLD and employs 99 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Anteo Diagnostics Limited to your portfolio

Top Management

Anteo Diagnostics Limited Leadership Team
Nobuyoshi Maeji, Executive, Ph.D
Alan Studley, Director, CPA
Mark Bouris, Chairman
Peter HardingSmith, CFO
Matthew Sanderson, Director
John Hurrell, Director, Ph.D
Stefan Enderling, CEO, Ph.D
Geoffrey Cumming, CEO
Tamara Mills, COO
Julien McInally, Executive, CPA
Shane Hartwig, Executive
Nevin Abernethy, Executive
Richard Martin, Director
Jef Vangenechten, CEO, Ph.D
Rolf Sickman, Director
Sandra Andersen, Director, CPA

Stock Performance

Anteo Diagnostics Performance Indicators